Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.
Clinical trials during COVID-19.
Site and patient identification, enrolment and engagement.
ICON provides its full range of clinical, consulting and commercial services across several sectors.
The new EU medical and in vitro diagnostic device regulations go into effect at the start of 2021. Are you ready?
Serving governments, multinational public health organisations, and global NGOs.
We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.
ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.
We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
Connecting patients with the right trial in the right location.
BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.
Aggregated news on COVID-19 clinical trials.
Reduce post market study costs with Real World Data.
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
30 July 2020
8 September 2020
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.
Partners Making a Difference.
The webinar explores new regulatory developments in both the US and Europe and how they are promoting a radical change to accelerate the approval of new medications for rare disease.
52:45
